1162264-07-4
1162264-07-4
Chemical Structure
LY2623091
- CAS. Nr.: 1162264-07-4
- Formula:C30H30FN5O3
- Molecular Weight:527.59
IUPAC Name: (R,E)-1-(5-((3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)methyl)-1-(1-morpholinopropan-2-yl)-1H-benzo[d]imidazol-2-yl)urea
InChIKey: YPCLDHGBEKZGEB-RUDKWAFVSA-N
SMILES: FC1=CC=C(C(OCC2=CC=CC=C/32)=C1)C3=C\C4=CC=C(N([C@H](C)CN5CCOCC5)C(NC(N)=O)=N6)C6=C4
Biological Activity: LY2623091 is a mineralocorticoid receptor antagonist for the treatment of refractory hypertension. LY2623091 exhibits CYP3A4-dependent clearance and synergistic effects with CYP3A4 inhibitors[1][2].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
LY2623091 | LY2623091 is a mineralocorticoid receptor antagonist for the treatment of refractory hypertension. LY2623091 exhibits CYP3A4-dependent clearance and synergistic effects with CYP3A4 inhibitors. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Dickinson G L, et al. Physiologically based pharmacokinetic modeling to understand the observed drug–drug interaction of LY2623091 with CYP3A inhibitors itraconazole and diltiazem[J]. International journal of Pharmacokinetics, 2017, 2(4): 233-245.
- [2]. Kocienski P. Synthesis of LY2623091[J]. Synfacts, 2017, 13(05): 0451.
Keywords
